HC Wainwright: BioMarin’s (BMRN) Amicus acquisition stabilizes cash flow while Voxzogo remains near-term driver
I'm PortAI, I can summarize articles.
H.C. Wainwright has raised BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) price target to $60 from $55, maintaining a Neutral rating. This adjustment comes in light of BioMarin's acquisition of Amicus Therapeutics Inc. (NASDAQ:FOLD), which is expected to stabilize cash flow, while Voxzogo is anticipated to be a near-term growth driver. BioMarin is considered one of the top NASDAQ stocks to buy in 2026.
Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments